Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma
The DOI matches its Crossref record.
Abstract
Purpose: Sarcomas are among the most proangiogenic malignancies in preclinical models. Phase I study results for ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, suggested activity in soft tissue sarcoma (STS) patients. This phase II study further evaluated the safety and efficacy of ABT-510 in advanced STS patients. Patients and Methods: Patients with metastatic or unresectable STS were randomly assigned to treatment with one of two ABT-510 dose schedules (20 mg once a day [20 mg], n = 42; or 100 mg twice a day [200 mg], n = 46), which were self-administered subcutaneously in 28-day treatment periods. End points included progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and safety. Results: Median PFS for the 20-mg arm was 94 days, with 4- and 6-month PFS rate estimates of 42% and 24%, respectively. Median PFS for the 200-mg arm was 64 days, with 4- and 6-month PFS rate estimates of 41% and 32%, respectively. Although only one objective response was noted, stable disease was observed in 52% (20 mg) and 48% (200 mg) of patients. Median OS was 431 days (20 mg) and 295 days (200 mg). ABT-510 was well tolerated. Rare treatment-related grade 3 or 4 adverse events were one event each of hypotension, deep vein thrombosis, and hypophosphatemia. ABT-510 pharmacokinetics were dose proportional, time independent, and consistent with those in previous studies. Conclusion: ABT-510 had a favorable safety profile, and the rate of disease control and OS times were encouraging. However, with low ORR and lack of dose response, the study failed to yield compelling evidence of strong single-agent activity in STS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532
“The efficacy of ABT-510 as a single rescue agent in patients with advanced soft tissue sarcomas was recently assessed in a phase II clinical trial (Baker et al. 2008).”
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2561 · Cited by 305
Omatsu, M., Nakanishi, Y., Iwane, K., Aoyama, N., Duran, A., Muta, Y., Martinez-Ordoñez, A., Han, Q., Agatsuma, N., Mizukoshi, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41095-y · Cited by 109
“…of THBS1 on vascularization failed to demonstrate bene fi cial ef fi cacy in metastatic melanoma, advanced renal cell carcinoma, and softtissuesarcoma 13 – 15 ,suggestingthatreducedvascularityinducedby THBS1 may play a key role in creating a therapy-resistant micro-environment in aggressive tumors.”
Metadata
- Authors
- Baker, L. H., Rowinsky, E. K., Mendelson, D., Humerickhouse, R. A., Knight, R. A., Qian, J., Carr, R. A., Gordon, G. B., & Demetri, G. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-12-01
- Volume
- 26
- Issue
- 34
- Pages
- 5583-5588
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1966309113
- Cited by
- 87
- References
- 0
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma. https://app.cochat.ai/papers/10.1200/jco.2008.17.4706
- The paper
- Baker, L. H., Rowinsky, E. K., Mendelson, D., Humerickhouse, R. A., Knight, R. A., Qian, J., Carr, R. A., Gordon, G. B., & Demetri, G. D. (2008). Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.4706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.